IT - EN
News & Announcements

News & AnnouncementsBusiness & financial news

2021, July 29 - 12:04 RECORDATI: FIRST HALF OF 2021 RESULTS APPROVED, REVENUE +1.4%, EBITDA -3.4%, NET INCOME +5.2%. RETURN TO GROWTH IN THE SECOND QUARTER
2021, July 16 - 07:31 RECORDATI: Rob Koremans new Chief Executive Officer effective 1 December 2021, Andrea Recordati to be appointed as Chairman.
2021, July 14 RECORDATI SUPPORTS THE FORESTAMI PROJECT
2021, July 9 - 07:50 STRENGTHENING OF THE CORPORATE GOVERNANCE
2021, May 25 THE TENTH EDITION OF THE ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH HAS ANNOUNCED THE CALL FOR APPLICATIONS
2021, May 6 - 13:12 RECORDATI: FIRST QUARTER 2021 RESULTS AND 2021-2023 THREE-YEAR PLAN APPROVED; 2023 REVENUE FORECAST BETWEEN € 1,900 AND € 2,000 MILLION
2021, April 28 - 09:37 RECORDATI TO PRESENT THE FIRST QUARTER 2021 RESULTS AND THE 2021-2023 STRATEGY AND OUTLOOK UPDATE
2021, April 22 - 12:22 RECORDATI: REGISTRATION WITH THE COMPANIES’ REGISTER OF THE MERGER DEED BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. COMPLETED
2021, April 20 - 12:47 RECORDATI: SHAREHOLDERS APPROVE THE 2020 ACCOUNTS. DIVIDEND € 1.05 PER SHARE (+5.0% vs 2019).
2021, April 12 - 18:13 RECORDATI: THE MERGER DEED RELATING TO THE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. HAS BEEN EXECUTED
2021, March 24 RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED IN JAPAN
2021, March 23 RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE
2021, March 18 - 16:42 RECORDATI: BOARD APPROVES THE 2020 ACCOUNTS. SALES € 1,448.9 MILLION (-2.2%), EBITDA € 569.3 MILLION (+4.7%), ADJUSTED NET INCOME € 410.4 MILLION (+7.3%). 2020 DIVIDEND € 1.05 (+ 5.0 %)
2021, February 22 - 18:25 RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS
2021, February 22 - 12:58 RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING AND NET INCOME. EBITDA +4.7% AND ADJ NET INCOME +7.3%
2021, January 29 - 18:06 RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES
2021, January 26 RECORDATI: CARBAGLU receives U.S. FDA Approval for a New Indication to Treat Acute Hyperammonemia Associated with Propionic Acidemia and Methylmalonic Acidemia
= price sensitive (as from 2015)